Data Gold 5 November, Citi released a research report stating that Sinda Bio (01801.HK) announced the termination of Fortvita subscription transactions. The company's management stated at an investor conference on November 4 that the original intention of the transaction was to accelerate the development of the company's overseas business, Fortvita, and after the termination of the transaction, there is currently no further financing plan for Fortvita. Since the announcement of the transaction, the group's stock price has fallen by more than 20%. Looking ahead, the bank believes that the group's strong sales performance and overseas progress will sustainably restore investor confidence. Rated "Buy", target price of 55 Hong Kong dollars.
Lihat Asli
Halaman ini mungkin berisi konten pihak ketiga, yang disediakan untuk tujuan informasi saja (bukan pernyataan/jaminan) dan tidak boleh dianggap sebagai dukungan terhadap pandangannya oleh Gate, atau sebagai nasihat keuangan atau profesional. Lihat Penafian untuk detailnya.
Citi: Beri peringkat "beli" untuk Innovent Biologics dengan target harga 55 dolar Hong Kong
Data Gold 5 November, Citi released a research report stating that Sinda Bio (01801.HK) announced the termination of Fortvita subscription transactions. The company's management stated at an investor conference on November 4 that the original intention of the transaction was to accelerate the development of the company's overseas business, Fortvita, and after the termination of the transaction, there is currently no further financing plan for Fortvita. Since the announcement of the transaction, the group's stock price has fallen by more than 20%. Looking ahead, the bank believes that the group's strong sales performance and overseas progress will sustainably restore investor confidence. Rated "Buy", target price of 55 Hong Kong dollars.